|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:acquiredBy
|
gptkb:AbbVie_Inc.
|
|
gptkbp:acquisitionYear
|
2020
|
|
gptkbp:category
|
companies formerly listed on the NYSE
companies based in Dublin
pharmaceutical companies of Ireland
|
|
gptkbp:CEO
|
gptkb:Brent_Saunders
|
|
gptkbp:focus
|
women's health
gastroenterology
urology
central nervous system
eye care
medical aesthetics
specialty drugs
|
|
gptkbp:founded
|
1948
|
|
gptkbp:founder
|
gptkb:Gavin_S._Herbert
|
|
gptkbp:headquartersLocation
|
gptkb:Dublin,_Ireland
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Allergan plc
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:mergedInto
|
gptkb:Actavis_plc
2015
|
|
gptkbp:movedTo
|
gptkb:Ireland_(2015)
|
|
gptkbp:netIncome
|
$3.6 billion (2018)
|
|
gptkbp:notableEvent
|
acquisition by AbbVie (2020)
tax inversion to Ireland (2015)
|
|
gptkbp:notableProduct
|
gptkb:Botox
gptkb:Juvederm
gptkb:Latisse
gptkb:Ozurdex
gptkb:Restasis
|
|
gptkbp:numberOfEmployees
|
17,400
|
|
gptkbp:origin
|
gptkb:Los_Angeles,_California,_USA
|
|
gptkbp:parentCompany
|
gptkb:AbbVie_Inc.
|
|
gptkbp:predecessor
|
gptkb:Allergan,_Inc.
|
|
gptkbp:revenue
|
$15.78 billion (2018)
|
|
gptkbp:servesArea
|
worldwide
|
|
gptkbp:status
|
defunct (as independent company)
|
|
gptkbp:stockExchange
|
gptkb:New_York_Stock_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:AGN
|
|
gptkbp:tradedOn
|
gptkb:NYSE:_AGN
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.allergan.com
|
|
gptkbp:bfsParent
|
gptkb:Allergan,_Inc.
gptkb:Actavis
|
|
gptkbp:bfsLayer
|
7
|